The addition of this inhibitor to intensive chemotherapy has dramatically improved the outlook for these children, increasing the rate of three-year event-free survival from 35% to 80%.
L'ajout de cet inhibiteur à la chimiothérapie intensive a considérablement amélioré les perspectives de ces enfants, ce qui augmente le taux de survie de trois ans sans risque de 35% à 80%.